8-K: Brainstorm Cell Therapeutics Delisted from Nasdaq, Shifts to OTCQB

Brainstorm Cell Therapeutics Inc. announced its common stock will be delisted from the Nasdaq Capital Market due to non-compliance with minimum shareholder equity requirements and will transition to trading on the OTCQB Venture Market.

Summary

• Brainstorm Cell Therapeutics Inc. (BCLI) received notification from The Nasdaq Stock Market LLC regarding the delisting of its common stock from the Nasdaq Capital Market.
• The delisting is a result of the company's previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), which pertains to its minimum shareholder equity requirement.
• Trading of BrainStorm's common stock on Nasdaq will be suspended effective at the open of trading on July 18, 2025.
• The company has applied for and been approved to have its common stock quoted on the OTC Markets OTCQB market tier.
• Trading on the OTCQB market tier is expected to commence at the open of trading on July 18, 2025, or as soon as possible thereafter, under the current trading symbol, BCLI.
• The company states that the transition to OTC Markets will have no effect on its business or operations.
• BrainStorm will continue to file periodic and other required reports with the Securities and Exchange Commission (SEC).

Sentiment

Score: 3

Explanation: The delisting from Nasdaq due to non-compliance with financial requirements is a significant negative event, indicating financial weakness and potentially reduced investor confidence and liquidity. While the company emphasizes continuity of operations and clinical programs, the move to OTCQB is generally viewed unfavorably by the market.

Positives

• Secured approval for common stock to be quoted on the OTCQB Venture Market, ensuring continuous trading for shares.
• The company states the delisting does not impact its business operations, ongoing research and development efforts, or commitment to shareholders.
• Remains fully dedicated to ongoing scientific and clinical programs, including preparations for a pivotal Phase 3b trial for NurOwn under a Special Protocol Assessment (SPA) agreement with the FDA.
• Will continue to provide updates on progress and financial status in compliance with applicable SEC regulations.
• Received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, strengthening its IP portfolio.

Negatives

• Delisted from the Nasdaq Capital Market.
• Delisting is due to non-compliance with Nasdaq Listing Rule 5550(b)(1), specifically the minimum shareholder equity requirement.
• Trading on Nasdaq will be suspended effective at the open of trading on July 18, 2025.
• Transition to the OTCQB market tier may result in reduced liquidity and investor visibility compared to Nasdaq.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions.
• Important factors outlined under the caption Risk Factors in the company's Annual Report on Form 10-K filed on March 31, 2025, and Quarterly Report on Form 10-Q filed on May 15, 2025.
• Management's ability to successfully achieve its goals.
• Ability to raise additional capital.
• Ability to continue as a going concern.
• Prospects for future regulatory approval of NurOwn.
• Whether future interactions with the FDA will have productive outcomes.

Future Outlook

The company expects its common stock to commence trading on the OTCQB market tier on July 18, 2025, or as soon as possible thereafter. It remains fully dedicated to its ongoing scientific and clinical programs, including preparations for a pivotal Phase 3b trial for NurOwn under a Special Protocol Assessment (SPA) agreement with the FDA. The company also continues to advance a proprietary, allogeneic exosome-based platform.

Management Comments

• "While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission or our unwavering commitment to advancing NurOwn for ALS patients." Chaim Lebovits, CEO of BrainStorm Cell Therapeutics.
• "Our pre-arranged transition to OTCQB ensures continuous trading for our shares and allows us to focus entirely on NurOwn's development." Chaim Lebovits, CEO of BrainStorm Cell Therapeutics.
• "We remain fully dedicated to our ongoing scientific and clinical programs, including preparations for our pivotal Phase 3b trial under the Special Protocol Assessment (SPA) agreement with the FDA." Chaim Lebovits, CEO of BrainStorm Cell Therapeutics.

Industry Context

This announcement highlights the financial challenges faced by some biotech companies, particularly those in the clinical development stage for neurodegenerative diseases like ALS, which require significant capital and have high failure rates. The transition from a major exchange like Nasdaq to OTCQB is a common outcome for companies unable to meet listing requirements, often signaling financial distress or a shift in investor base. However, the company's continued focus on its NurOwn platform and the upcoming Phase 3b trial under SPA indicates ongoing commitment to its core therapeutic development, which is typical for a biotech firm aiming for regulatory approval. The mention of an exosome-based platform also shows diversification into emerging areas of regenerative medicine.

Stakeholder Impact

• Shareholders: Will experience a delisting from Nasdaq, potentially leading to reduced liquidity, lower visibility, and a perception of increased risk. Shares will transition to OTCQB.
• Patients: The company assures that the delisting does not alter its core mission or commitment to advancing NurOwn for ALS patients, suggesting continued development efforts.
• Employees: No direct impact on employment or operations mentioned, implying continuity.

Next Steps

• Commence trading of common stock on the OTCQB market tier on July 18, 2025, or as soon as possible thereafter.
• Continue to file periodic and other required reports with the SEC.
• Continue ongoing scientific and clinical programs, including preparations for a pivotal Phase 3b trial for NurOwn under a Special Protocol Assessment (SPA) agreement with the FDA.
• Continue advancing the proprietary, allogeneic exosome-based platform.

Key Dates

Recommendation

Keywords

Brainstorm Cell Therapeutics, BCLI, Nasdaq delisting, OTCQB, NurOwn, ALS, neurodegenerative diseases, stem cell therapy, SEC filing, 8-K, biotechnology, clinical trials, Phase 3b, FDA, Special Protocol Assessment, exosome technology